This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Bioverativ | |
|---|---|
| Name | Bioverativ |
| Type | Subsidiary |
| Industry | Biotechnology |
| Founded | 2016 |
| Fate | Acquired by Sanofi (2018) |
| Headquarters | Cambridge, Massachusetts, United States |
| Products | Hematology therapeutics |
Bioverativ
Bioverativ was a biotechnology company focused on therapies for hemophilia and other rare hematologic disorders. Headquartered in Cambridge, Massachusetts, it emerged from a corporate spin-out and engaged with global regulatory bodies, academic centers, and commercial partners. The company operated in a landscape populated by multinational pharmaceutical firms, academic research institutions, patient advocacy organizations, and investment markets.
Bioverativ was formed in 2016 following the corporate restructuring of a multinational pharmaceuticals division tied to Sanofi during an era of industry consolidation involving entities such as Pfizer, Novartis, Roche, GlaxoSmithKline, Bristol-Myers Squibb, Merck & Co., AstraZeneca, Eli Lilly and Company, Johnson & Johnson, AbbVie, Takeda Pharmaceutical Company, Bayer, Amgen, Regeneron Pharmaceuticals, Gilead Sciences, Celgene, Biogen, Shire plc, Teva Pharmaceutical Industries, Allergan, Kite Pharma, Vertex Pharmaceuticals, Alexion Pharmaceuticals, Sarepta Therapeutics, Ionis Pharmaceuticals, Novo Nordisk, Mallinckrodt Pharmaceuticals, Sun Pharmaceutical Industries, Hoffmann-La Roche/Genentech, CSL Limited, Ipsen, Lundbeck, and Endo International. The spin-off leveraged intellectual property and assets originating from collaborations with academic centers such as Harvard University, Massachusetts Institute of Technology, University of Cambridge, University of Oxford, Stanford University, Johns Hopkins University, University of Pennsylvania, Duke University, Imperial College London, University College London, Karolinska Institutet, McGill University, University of Toronto, University of California, San Francisco, Yale University, Columbia University, University of Chicago, Princeton University, Massachusetts General Hospital, and Brigham and Women's Hospital. Shortly after formation, Bioverativ engaged in strategic partnerships and licensing discussions with companies like Shire plc, Baxalta, Horizon Therapeutics, Sobi (Swedish Orphan Biovitrum), Ferring Pharmaceuticals, Alnylam Pharmaceuticals, Bluebird Bio, CRISPR Therapeutics, Sangamo Therapeutics, and Editas Medicine. In 2018, Bioverativ became a target of acquisition and was acquired by Sanofi, integrating its hematology portfolio into a larger corporate framework alongside business units of multinational competitors and peers.
Bioverativ's portfolio centered on blood disorder therapeutics, particularly treatments for hemophilia A and hemophilia B, and other rare hematologic conditions. Clinical programs drew on technologies and precedents from companies and institutions including Genentech, Baxter International, Bayer AG, Novo Nordisk, UniQure, Spark Therapeutics, Kite Pharma, Sarepta Therapeutics, Bluebird Bio, Shire plc, CSL Behring, Octapharma, Grifols, Takeda Pharmaceutical Company, Pfizer, Roche, and Amgen. Research pipelines employed methods and trial designs influenced by regulatory decisions from agencies such as the U.S. Food and Drug Administration, the European Medicines Agency, and the Pharmaceuticals and Medical Devices Agency of Japan, mirroring approaches seen in programs led by Alexion Pharmaceuticals and Regeneron Pharmaceuticals. Bioverativ's clinical-stage therapeutics referenced standards established in landmark trials involving investigators from Massachusetts General Hospital, Mayo Clinic, Cleveland Clinic, Hospital for Sick Children (Toronto), St. Jude Children's Research Hospital, Children's Hospital of Philadelphia, Karolinska University Hospital, Royal Free Hospital, Guy's and St Thomas' NHS Foundation Trust, Addenbrooke's Hospital, and Royal Children's Hospital Melbourne.
Bioverativ operated as a corporate entity with a board and executive team drawn from backgrounds spanning biotechnology and pharmaceuticals, including executives with prior roles at Genzyme Corporation, Biogen, Genentech, Amgen, Pfizer, Sanofi, Shire plc, Baxter International, Takeda Pharmaceutical Company, CSL Limited, Alexion Pharmaceuticals, Eli Lilly and Company, Novartis, Roche, Bristol-Myers Squibb, Gilead Sciences, Regeneron Pharmaceuticals, Vertex Pharmaceuticals, Sarepta Therapeutics, Alnylam Pharmaceuticals, Bluebird Bio, Sangamo Therapeutics, and CRISPR Therapeutics. Governance structures reflected norms shared with pharmaceutical boards that have overseen mergers and acquisitions involving AstraZeneca, Merck & Co., GlaxoSmithKline, Johnson & Johnson, and AbbVie. The company maintained corporate functions in finance, clinical development, regulatory affairs, and commercial operations aligned with partner organizations including IQVIA, PAREXEL International, ICON plc, Covance, Charles River Laboratories, LabCorp, Quest Diagnostics, McKinsey & Company, Boston Consulting Group, Deloitte, PricewaterhouseCoopers, and Ernst & Young.
As an independent public company and later as an acquisition target, Bioverativ's financial narrative intersected with capital markets activities commonly associated with Nasdaq, New York Stock Exchange, institutional investors such as BlackRock, Vanguard Group, Fidelity Investments, Goldman Sachs, Morgan Stanley, J.P. Morgan Chase, Bank of America Merrill Lynch, Citigroup, Barclays, Deutsche Bank, Credit Suisse, UBS, and private equity firms akin to KKR, The Carlyle Group, and TPG Capital. The 2018 acquisition by Sanofi represented a significant transaction in the hematology sector comparable to acquisitions involving Shire plc and Baxalta. Bioverativ also engaged in licensing, collaboration, and milestone arrangements similar to deals completed by Novartis and Roche.
Bioverativ's clinical programs and commercialization efforts were subject to oversight by regulatory bodies including the U.S. Food and Drug Administration, the European Medicines Agency, the Pharmaceuticals and Medical Devices Agency, and national health authorities across regions such as NICE in the United Kingdom and agencies in Health Canada, Australian Therapeutic Goods Administration, ANVISA, and Swissmedic. The company navigated intellectual property portfolios and patent landscapes interacting with filers such as Genentech, UniQure, Spark Therapeutics, Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Sarepta Therapeutics, CRISPR Therapeutics, Editas Medicine, and Sangamo Therapeutics. Legal considerations paralleled litigation and regulatory reviews seen in disputes involving Amgen, Regeneron Pharmaceuticals, Vertex Pharmaceuticals, Biogen, and Alexion Pharmaceuticals.
Bioverativ participated in patient advocacy and philanthropic efforts aligned with organizations such as World Federation of Hemophilia, Haemophilia Foundation Australia, National Hemophilia Foundation, UK Haemophilia Society, Red Cross, UNICEF, Bill & Melinda Gates Foundation, Robert Wood Johnson Foundation, Michael J. Fox Foundation, American Red Cross, Campaign for Safe Cosmetics, Doctors Without Borders, The Wellcome Trust, Howard Hughes Medical Institute, Cystic Fibrosis Foundation, Leukemia & Lymphoma Society, American Heart Association, American Cancer Society, and regional patient groups. Corporate giving and educational programs reflected practices observed at peers including Genentech, Biogen, Johnson & Johnson, Roche, and Novartis.